Bioplasma Tablet, Soluble
NDC Package 54973-4086-1
Package Information
Bioplasma (silicon dioxide, potassium chloride, sodium sulfate, ferrosoferric phosphate, magnesium phosphate, dibasic trihydrate, sodium phosphate, dibasic, heptahydrate, tribasic calcium phosphate, potassium phosphate, dibasic, potassium sulfate, sodium chloride, calcium sulfate anhydrous, calcium fluoride) tablets is ■ Use as directed. This formulation utilizes a tablet, soluble delivery system. Marketed by Hyland's Inc., this product is identified by NDC 54973-4086.
Identification & Billing
Clinical Specifications
- CALCIUM FLUORIDE 6 [hp_X]/1
- CALCIUM SULFATE ANHYDROUS 3 [hp_X]/1
- FERROSOFERRIC PHOSPHATE 3 [hp_X]/1
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 3 [hp_X]/1
- POTASSIUM CHLORIDE 3 [hp_X]/1
- POTASSIUM PHOSPHATE, DIBASIC 3 [hp_X]/1
- POTASSIUM SULFATE 3 [hp_X]/1
- SILICON DIOXIDE 6 [hp_X]/1
- SODIUM CHLORIDE 6 [hp_X]/1
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 3 [hp_X]/1
- SODIUM SULFATE 3 [hp_X]/1
- TRIBASIC CALCIUM PHOSPHATE 3 [hp_X]/1
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Potassium Compounds - [CS]
- Potassium Salt - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 54973 - Hyland's Inc.
- 54973-4086 - Bioplasma
- 54973-4086-1 - 1 BOTTLE, PLASTIC in 1 CARTON / 100 TABLET, SOLUBLE in 1 BOTTLE, PLASTIC
- 54973-4086 - Bioplasma
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 54973-4086-1 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 100 tablet, soluble in 1 bottle, plastic of Bioplasma, a human over the counter drug labeled by Hyland's Inc.. This tablet, soluble is formulated for oral use and contains calcium fluoride; calcium sulfate anhydrous; ferrosoferric phosphate; magnesium phosphate, dibasic trihydrate; potassium chloride; potassium phosphate, dibasic; potassium sulfate; silicon dioxide; sodium chloride; sodium phosphate, dibasic, heptahydrate; sodium sulfate; tribasic calcium phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hyland's Inc. on December 06, 2021. The current certification is valid through December 31, 2026.
How is this Hyland's Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 54973408601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.